Get the Stockscreener App
12.62
2.89%
0.355
After Hours:
12.63
0.01
+0.08%
Intellia Therapeutics Inc stock is traded at $12.62, with a volume of 14.20M.
It is up +2.89% in the last 24 hours and down -26.93% over the past month.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$12.27
Open:
$12.55
24h Volume:
14.20M
Relative Volume:
2.04
Market Cap:
$1.35B
Revenue:
$52.86M
Net Income/Loss:
$-480.19M
P/E Ratio:
-2.6909
EPS:
-4.6899
Net Cash Flow:
$-421.82M
1W Performance:
-50.70%
1M Performance:
-26.93%
6M Performance:
+42.28%
1Y Performance:
-11.25%
1-Day Range:
$12.13
$13.38
1-Week Range:
$11.63
$16.76
52-Week Range:
$5.90
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
12.62 | 1.32B | 52.86M | -480.19M | -421.82M | -4.6899 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-28-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-27-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-27-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Apr-21-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-05-25 | Initiated | H.C. Wainwright | Buy |
| Feb-28-25 | Downgrade | Goldman | Neutral → Sell |
| Feb-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-27-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-23-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Sell |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Jun-16-22 | Initiated | BofA Securities | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Feb-18-22 | Initiated | William Blair | Outperform |
| Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-22 | Initiated | Cowen | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
| Oct-05-21 | Initiated | Guggenheim | Buy |
| Sep-24-21 | Initiated | Stifel | Buy |
| Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-11-21 | Initiated | H.C. Wainwright | Buy |
| May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-27-20 | Initiated | Truist | Buy |
| Oct-14-20 | Initiated | Wells Fargo | Overweight |
| Sep-18-20 | Initiated | Goldman | Buy |
| Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-09-19 | Initiated | Robert W. Baird | Outperform |
| Jun-10-19 | Initiated | ROTH Capital | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-29-18 | Initiated | Credit Suisse | Neutral |
| Sep-21-18 | Initiated | Raymond James | Mkt Perform |
| May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
| Nov-01-17 | Reiterated | Jefferies | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130% - sharewise.com
Should You Buy Viking Therapeutics Before Nov. 5? - AOL.com
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130% - The Motley Fool
Real time scanner hits for Intellia Therapeutics Inc. explainedOil Prices & Risk Managed Investment Signals - newser.com
Is Intellia Therapeutics Inc. (38I) stock a buy on weakness2025 Momentum Check & Stock Portfolio Risk Management - newser.com
Can a trend reversal in Intellia Therapeutics Inc. lead to recoveryJuly 2025 Breakouts & AI Enhanced Trade Execution Alerts - newser.com
How sentiment analysis helps forecast Intellia Therapeutics Inc.Quarterly Trade Report & High Accuracy Swing Trade Signals - newser.com
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Is Intellia Therapeutics Inc. (38I) stock trading at attractive multiples2025 Dividend Review & Short-Term High Return Ideas - newser.com
Will Intellia Therapeutics Inc. (38I) stock benefit from sector leadershipWeekly Profit Summary & Long-Term Capital Growth Strategies - newser.com
Relative strength of Intellia Therapeutics Inc. in sector analysisTrade Signal Summary & AI Forecasted Entry/Exit Points - newser.com
Leerink Partnrs Has Positive Estimate for NTLA Q3 Earnings - MarketBeat
What to expect from Intellia Therapeutics Inc. in the next 30 days2025 Analyst Calls & Momentum Based Trading Signals - newser.com
Intellia Therapeutics Inc. (NTLA) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Intellia Stock Downgraded After Trial Pause Raises Safety Concerns, BofA Says - MarketScreener
SA analyst upgrades/downgrades: AMZN, NVDA, CMG, NTLA - Seeking Alpha
Liver Complications Lead FDA to Stop Tests of Intellia Gene-Editing Therapy for a Rare Disease - MedCity News
Intellia Therapeutics: Irreversible Edit Vs. Reversible SOCs Now A Hard Sell (Rating Downgrade) - Seeking Alpha
Gene-editing stocks rally on Bloomberg report that FDA plans to fast-track approval process - Sherwood News
FDA Clears Way for Faster Personalized Gene Editing Therapy - Bloomberg.com
NTLA FY2027 EPS Reduced by Brookline Capital Management - MarketBeat
What is Leerink Partnrs' Estimate for NTLA FY2027 Earnings? - MarketBeat
Is a relief rally coming for Intellia Therapeutics Inc. holders2025 Retail Activity & Free Real-Time Market Sentiment Alerts - newser.com
Is Intellia Therapeutics Inc. still worth holding after the dipJuly 2025 Sentiment & Long-Term Safe Investment Plans - newser.com
Analyzing drawdowns of Intellia Therapeutics Inc. with statistical tools2025 Historical Comparison & Advanced Swing Trade Entry Plans - newser.com
Chart overlay techniques for tracking Intellia Therapeutics Inc.2025 Major Catalysts & Verified Momentum Stock Alerts - newser.com
How cyclical is Intellia Therapeutics Inc. (38I) stock compared to rivalsFed Meeting & Intraday High Probability Alerts - newser.com
What technical models suggest about Intellia Therapeutics Inc.’s comeback2025 Historical Comparison & AI Powered Buy and Sell Recommendations - newser.com
Will Intellia Therapeutics Inc. stock benefit from AI adoptionJobs Report & Growth Oriented Trading Recommendations - newser.com
Is Intellia Therapeutics Inc. stock oversold or undervaluedMarket Volume Summary & Free Technical Pattern Based Buy Signals - newser.com
Intellia Therapeutics Faces FDA Clinical Hold on Trials - The Globe and Mail
Intellia: Moving To 'Hold' Rating In Light Of Nex-Z Uncertainty In ATTR Patients (Downgrade) - Seeking Alpha
NTLA Stock: Plummet Unlocks Market Debate? - StocksToTrade
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Down 7.9% on Analyst Downgrade - MarketBeat
HC Wainwright & Co. Lowers NTLA Price Target to $18, Maintains B - GuruFocus
FDA places formal hold on two Intellia CRISPR trials - BioPharma Dive
FDA puts two Intellia CRISPR trials on hold following liver toxicity case - Endpoints News
Intellia Therapeutics (NASDAQ:NTLA) Lowered to "Hold" Rating by Wells Fargo & Company - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Rating Lowered to Sector Perform at Royal Bank Of Canada - MarketBeat
Life-Threatening Liver Toxicity Triggers FDA Freeze on Two Intellia Gene Therapy Studies - BioSpace
FDA places Intellia phase 3 CRISPR trials on hold over raised liver enzymes - Fierce Biotech
Biotech might be tiny but the dealmaking is mighty - statnews.com
Intellia Therapeutics stock price target lowered to $9 at Baird on FDA hold - Investing.com
Intellia falls as FDA places clinical hold on its gene therapy trials - TradingView
D.A. Davidson & CO. Grows Stock Holdings in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics (NTLA) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
What data driven models say about Intellia Therapeutics Inc.’s futureJuly 2025 Market Mood & Low Drawdown Investment Strategies - newser.com
Intellia Therapeutics Powers Biotech Progress on Nasdaq Today - Kalkine Media
Why retail investors pile into Intellia Therapeutics Inc. stock2025 Breakouts & Breakdowns & Technical Pattern Recognition Alerts - newser.com
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):